FDA 483 - PETNET Solutions Inc - April 21, 2023

An FDA inspection of PETNET Solutions Inc's Pet Drug Corporate Headquarters in Knoxville, TN, revealed significant deficiencies in laboratory controls and manufacturing processes. Observations included unsuitable analytical methods, a lack of established specifications for PET drug products, and inadequate process controls for in-process materials. These issues indicate potential risks to product quality and purity.